RecruitingNCT04354545

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications


Sponsor

University of California, Los Angeles

Enrollment

75 participants

Start Date

Apr 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study is evaluating a prescription eye drop called Xiidra (lifitegrast) for reducing eye surface discomfort in glaucoma patients who use multiple eye drops to control their eye pressure. Long-term use of glaucoma drops can irritate the surface of the eye, and Xiidra may help relieve that discomfort. **You may be eligible if:** - You are currently using one or more topical glaucoma eye drops to lower eye pressure - You experience symptoms of eye surface discomfort (dryness, irritation, etc.) - Xiidra has been prescribed as part of your standard glaucoma care **You may NOT be eligible if:** - You have had glaucoma filtering surgery or eye surface surgery (such as pterygium removal) - You are currently using topical cyclosporine eye drops - You are currently using topical steroid eye drops - You have had eye surgery within the past 6 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGXiidra (Lifitegrast ophthalmic solution) 5%

FDA approved lifitegrast opthalmic solution eye drop


Locations(1)

Doheny Eye Center UCLA

Fountain Valley, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04354545


Related Trials